SEOM‑TTCC clinical guideline for nasopharyngeal carcinoma (update 2025)
Radiotherapy (RT) is the cornerstone of locoregional treatment for NPC.
Nasopharyngeal carcinoma is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiotherapy is the cornerstone of locoregional treatment of non‑disseminated disease and, in combination with chemotherapy, improves survival rates. In the case of metastatic disease stages, treatment requires platinum/gemcitabine‑based chemotherapy, and patients may achieve a long survival time. In these guidelines (updated in 2025), we summarize current evidence and available therapies for the medical management of advanced nasopharyngeal carcinoma.
Radiotherapy is the main modality for definitive local‑regional control of nasopharyngeal carcinoma. When delivered with intensity‑modulated techniques, it achieves high survival rates and limits late toxicities, and it is the basis for combined modality therapy that improves overall and disease‑specific survival. Optimising RT dose, field, and schedule is therefore essential for good oncologic outcomes in this disease.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Anti‑PD‑1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double‑blind phase 3 study
- Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma
- Nasopharyngeal Cancer
- Hierarchical dynamic model for risk‑stratified screening of nasopharyngeal carcinoma
- Expert consensus on the role of immunotherapy in nasopharyngeal carcinoma: clinical and economic perspectives from the GCC region